3 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow AegisCN LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of CN-105 in Subject With Acute Supratentorial Intracerebral Hemorrhage Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2)., 0.9% Sodium-chloride - Intracerebral Hemorrhage | Phase 2 | Completed | National Neuroscience Institute | 60 | 2019-03-24 | 2022-12-01 |
| A Proof of Concept Study to Evaluate CN-105 in ICH Patients CN-105 - Intracerebral Hemorrhage | Phase 2 | Completed | AegisCN LLC | 38 | 2017-08-28 | 2020-03-11 |
| Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage CN-105, Placebo - Intracerebral Hemorrhage (ICH) | Phase 1 | Completed | AegisCN LLC | 48 | 2015-12-01 | 2016-08-18 |
apolipoprotein E mimetic peptide CN-105 (2) · Sodium Chloride (1)
United States (2) · Singapore (1)
PMID 35562205, PMID 11161595, PMID 11590206, PMID 14671250, PMID 16179504, PMID 27713572, PMID 27990643, PMID 28429734, PMID 42332280, PMID 9184634